Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoine Italiano

Showing results (191-200 of 418) with videos related to

Pageof 42
Sort By:
Experimental Hematology & Oncology|January 8, 2024
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNAClémence Astier, Carine Ngo, Léo Colmet-Daage, et al.
Molecular Cancer|February 19, 2024
Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC studyCheng-Ming Sun, Maud Toulmonde, Mariella Spalato-Ceruso, et al.
The American Journal of Surgical Pathology|November 9, 2018
Clinicopathologic Features of CIC-NUTM1 Sarcomas, a New Molecular Variant of the Family of CIC-Fused SarcomasFrançois Le Loarer, Daniel Pissaloux, Sarah Watson, et al.
BMC Cancer|May 6, 2022
A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumorMaria A Pantaleo, Michael C Heinrich, Antoine Italiano, et al.
AJR. American Journal of Roentgenology|September 29, 2020
Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy-A Multicenter Study by the French Sarcoma GroupAmandine Crombé, Michèle Kind, Isabelle Ray-Coquard, et al.
European Journal of Cancer (Oxford, England : 1990)|July 28, 2017
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation studyEric Angevin, Philippe A Cassier, Antoine Italiano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2021
Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II TrialSophie Cousin, Coralie Cantarel, Jean-Philippe Guegan, et al.
NPJ Precision Oncology|October 7, 2024
Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trialsArnaud Bayle, Laila Belcaid, Sophie Cousin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2025
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03Afshin Dowlati, Anne C Chiang, Andrés Cervantes, et al.
JAMA Oncology|June 30, 2017
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical TrialMaud Toulmonde, Nicolas Penel, Julien Adam, et al.
Pageof 42

Showing results (191-200 of 418) with videos related to

Sort By:
Pageof 42
Experimental Hematology & Oncology|January 8, 2024
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNAClémence Astier, Carine Ngo, Léo Colmet-Daage, et al.
Molecular Cancer|February 19, 2024
Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC studyCheng-Ming Sun, Maud Toulmonde, Mariella Spalato-Ceruso, et al.
The American Journal of Surgical Pathology|November 9, 2018
Clinicopathologic Features of CIC-NUTM1 Sarcomas, a New Molecular Variant of the Family of CIC-Fused SarcomasFrançois Le Loarer, Daniel Pissaloux, Sarah Watson, et al.
BMC Cancer|May 6, 2022
A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumorMaria A Pantaleo, Michael C Heinrich, Antoine Italiano, et al.
AJR. American Journal of Roentgenology|September 29, 2020
Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy-A Multicenter Study by the French Sarcoma GroupAmandine Crombé, Michèle Kind, Isabelle Ray-Coquard, et al.
European Journal of Cancer (Oxford, England : 1990)|July 28, 2017
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation studyEric Angevin, Philippe A Cassier, Antoine Italiano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2021
Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II TrialSophie Cousin, Coralie Cantarel, Jean-Philippe Guegan, et al.
NPJ Precision Oncology|October 7, 2024
Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trialsArnaud Bayle, Laila Belcaid, Sophie Cousin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2025
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03Afshin Dowlati, Anne C Chiang, Andrés Cervantes, et al.
JAMA Oncology|June 30, 2017
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical TrialMaud Toulmonde, Nicolas Penel, Julien Adam, et al.
Pageof 42